Click it and Unblock the Notifications
Just In
Don't Miss
-
1:3 Bonus Share, Rs 13.25/Share Dividend: Buy Maharatna PSU, TP Rs 355, Fundraise Approved -
Kamada Ekadashi 2024 Wishes: Greetings, Messages, Texts, Images, Twitter Status And Instagram Captions -
Who Won Yesterday's IPL Match 33? PBKS vs MI, IPL 2024 on April 17: Mumbai Indians Escape Last-Ditched Fight by Punjab Kings To Win -
Do Aur Do Pyaar OTT Release Date & Platform: When & Where To Watch Vidya Balan’s Film After Theatrical Run? -
Aprilia RS 457 Accessories: A Detailed Look At The Prices -
Karnataka SSLC Result 2024 Soon, Know How to Check Through Website, SMS and Digilocker -
Nothing Ear, Ear a With ANC, Up to 42.5 Hours of Battery Launched; Check Price and Availability -
Telangana's Waterfall: A Serene Escape Into Nature's Marvels
Dr Reddy's subsidiary launches EPICERAM
Hyderabad, Oct 14 (UNI) Promius Pharma, LLC, a wholly-owned subsidiary of Dr Reddy's Laboratories, today announced the launch of its first product, EpiCeram Skin Barrier Emulsion.
EpiCeram Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million patients in the United States.
In a statement, Promius Pharma Executive Vice-President Jeffrey Wasserstein said, ''This product was developed to specifically address the defective skin barrier of atopic patients to safely and effectively control the signs and symptoms of atopic dermatitis.
EpiCeram Emulsion is our first commercialized product and it aligns with our core strategy of striving to meet unmet medical needs.
EpiCeram
has
the
potential
to
change
how
doctors
treat
mild
to
moderate
atopic
dermatitis.'' UNI
VA
GM1715
